-
New Test Looks at Unique Response of MS Patients to Epstein-Barr Virus
Clinical Research News | Significant evidence now exists implicating the Epstein-Barr virus (EBV) as a causal factor in the development of multiple sclerosis (MS), making treatment of the virus a priority. To that end, research scientists at Trinity College Dublin have developed a blood test to measure the immune response to EBV that could be used as an outcome measure in future clinical trials in people with established MS.
May 1, 2024
-
Bayesian Statistics: An Important Yet Underutilized Paradigm in Rare Disease and Small Population Drug Development
Clinical Research News | Advances in medical understanding and treatment approaches are driving a revolution in the rare disease space. Approaches such as gene therapies and biologics are offering previously unimagined opportunities to tackle unmet need, changing, and even saving, lives.
Apr 26, 2024
-
PathAI Enters Partnership With Google Cloud, Cardiometabolic Clinical Trials Platform, DNA/RNA Extraction Kits, More
Clinical Research News | PathAI announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology labs accelerate the adoption of AI and digital pathology; Clinical ink has launched GlucoseReady, a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials; New England Biolabs has released its Monarch Mag Viral DNA/RNA Extraction Kit, which enhances recovery of low amounts of viral nucleic acid to enable highly sensitive detection; more.
Apr 25, 2024
-
Follow the Money: Obesity Medicine Company Metsera Launched, Tumor-Infiltrating Lymphocyte Program, Novel Oncology Biologics, More
Clinical Research News | Metsera has launched and will rapidly advance a broad portfolio of oral and injectable incretin, nonincretin, and combination therapies designed to meet the future needs of a rapidly evolving weight loss treatment landscape; Obsidian Therapeutics plans to advance its lead engineered tumor-infiltrating lymphocyte program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer; TORL BioTherapeutics has publicly launched and plans to advance its pipeline of antibody-drug conjugates and monoclonal antibodies; more.
Apr 24, 2024
-
We Need a People-First Approach to Clinical Trial Technology
Clinical Research News | The proliferation of mobile technology—including multiple generations of progressively smarter phones, tablets, watches, and other devices—has set the stage for similar types of eClinical innovation. However, the two types of technologies have not progressed at the same pace. This is unfortunate for all clinical trial stakeholders and, most notably, patients.
Apr 19, 2024